Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics (NQ: HZNP )

93.55 USD +2.49 (+2.73%)
Official Closing Price Updated: 5:26 PM EDT, Apr 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Horizon Therapeutics

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
IBD Screen Of The Day: 4 Top-Notch Global Leaders Near Buy Points
Investors searching for hot stocks to buy or watch should check out IBD Screen Of The Day. Today, we feature global leaders near buy points. 
From Investor's Business Daily
HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout
- Second Milestone Achieved by HemoShear in Exclusive Drug Discovery Collaboration - 
From PR Newswire
Earnings Season Preview: Horizon Pharma Near Buy Zone With EPS Due
Horizon Pharma is near a possible buy area ahead of its earnings report expected around May 5 . 
From Investor's Business Daily
Noteworthy ETF Inflows: VB, GNRC, MDB, HZNP
Symbols mentioned in this story: VB, GNRC, MDB, HZNP Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units''... 
Tags ETFs
From ETF Channel
Forbion Announces Final Close of Forbion Growth Opportunities Fund I at EUR 360 Million (USD 428 Million)
Forbion, a leading European life sciences venture capital firm, today announces the final close of its Forbion Growth Opportunities Fund I (“Forbion Growth I") at the hard cap amount of EUR 360 million... 
From Business Wire News Releases
3 Reasons to Buy Horizon Therapeutics Stock and 1 Not To
Horizon Therapeutics's shares are up almost 200% over the past 12 months, buoyed by mind-boggling sales of its new blockbuster drug. 
Tags VIE CTLT Market News
From Motley Fool
New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Horizon Therapeutics today announced new UPLIZNA® (inebilizumab-cdon) data being presented at the American Academy of Neurology 2021 Annual Meeting. 
From Business Wire News Releases
New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology
Horizon Therapeutics announced pooled data from the TEPEZZA® (teprotumumab-trbw) clinical trials are published in The Lancet Diabetes & Endocrinology. 
From Business Wire News Releases
Biotech Stock On Earnings Win Streak Sets Up Bullish Chart
Biotech stock Horizon Therapeutics is set up below a buy point, ahead of earnings, after soaring 102% in 2020. Can it do it again? 
From Investor's Business Daily
Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has been named one of Fortune’s 100 Best Companies to Work For® in the United States. This is Horizon’s first time being included on the... 
From Business Wire News Releases
IBD Screen Of The Day: Four Growth Stocks Showing Rising Profit Estimates
Today's IBD Screen Of The Day column focuses on growth stocks showing rising profit estimates. It's one of several powerful screens found in the IBD Stock Screener. 
From Investor's Business Daily
Horizon Therapeutics plc to Release First-Quarter 2021 Financial Results and Host Webcast on May 5, 2021
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its first-quarter 2021 financial results will be released on Wednesday, May 5, 2021. Following the announcement, Horizon's management will... 
From Business Wire News Releases
RECIPE Randomized Controlled Trial Data Published in Arthritis & Rheumatology Show Higher Response Rates Using KRYSTEXXA® (pegloticase injection) with the Immunomodulator Mycophenolate Mofetil
Horizon Therapeutics plc (Nasdaq: HZNP) announced the publication of data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomitantly used with an... 
From Business Wire News Releases
Does 2021's Best Biopharma to Work for Belong in Your Portfolio?
Horizon Therapeutics has a clear path to significant sales growth. 
Tags BMY ABBV HZNP
From Motley Fool
New UPLIZNA® (inebilizumab-cdon) Data in People With Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the American Academy of Neurology’s 73rd Annual Meeting
Horizon Therapeutics announces new NMOSD data being presented at the American Academy of Neurology’s 73rd Annual Meeting. 
From Business Wire News Releases
IBD 50 Stocks To Buy And Watch: Square Headlines 6 Leaders Offering New Buy Points
Among the top IBD 50 stocks to buy and watch, Square stock is approaching a new buy point in the current stock market rally. 
From Investor's Business Daily
Horizon Pharma Meets 80-Plus Relative Strength Rating Benchmark
A Relative Strength Rating upgrade for Horizon Pharma shows improving technical performance. 
From Investor's Business Daily
Horizon Therapeutics plc to Resupply Market With TEPEZZA® (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Beginning in April
Horizon Therapeutics to resupply the market with TEPEZZA® (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED) beginning in April. 
From Business Wire News Releases
Horizon Therapeutics and Chicago Cubs Announce Legacy Partnership
Horizon Therapeutics (Nasdaq: HZNP) and the Cubs today announced a Legacy Partnership that includes a Cubs STEAM Program, presented by Horizon, which will include an innovative, citywide science camp... 
From Business Wire News Releases
First Patient Enrolls in FORWARD Trial to Evaluate Monthly Dosing of KRYSTEXXA® (pegloticase injection) and Methotrexate to Treat Uncontrolled Gout
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a clinical trial that will evaluate a monthly dosing regimen of 16 mg of KRYSTEXXA (pegloticase injection)... 
From Business Wire News Releases
UPLIZNA® (inebilizumab-cdon) Approved by Japanese Ministry of Health, Labour and Welfare for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its strategic partner Mitsubishi Tanabe Pharma Corporation (MTPC) has received manufacturing and marketing approval of UPLIZNA for the... 
From Business Wire News Releases
Horizon Therapeutics plc Launches The Horizon Prize with Massachusetts Institute of Technology (MIT) Solve to Advance Solutions for the Rare Disease Community
Horizon Therapeutics plc (Nasdaq: HZNP), in partnership with MIT Solve, a marketplace for social impact innovation, today announced it has created a first-of-its-kind annual global innovation challenge... 
From Business Wire News Releases
Interesting HZNP Put And Call Options For November 19th
Investors in Horizon Therapeutics plc (HZNP) saw new options become available this week, for the November 19th expiration. One of the key inputs that goes into the price an option buyer is willing to... 
Tags Stocks
From Market News Video
AstraZeneca to supply U.S. with extra 500,000 doses of COVID-19 antibody-based cocktail
AZD7442 is being evaluated for the prevention and treatment of COVID-19 in late-stage trials in more than 9,000 participants around the world. 
Tags MS AZN VIR
From MarketWatch
Few Top Global Growth Stocks To Buy And Watch On IBD's Screen Of The Day
Today's IBD Screen Of The Day focuses on top global stocks that feature solid IBD Ratings and are near new highs. 
From Investor's Business Daily
Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed the acquisition of Viela Bio, Inc. (Nasdaq: VIE) (“Viela”). 
From Business Wire News Releases
Best Stocks To Buy This Week? 4 Health Care Stocks To Watch
Tags Market News
From StockMarket.com
Horizon Therapeutics plc Named Number One Best Workplace in Biopharma
Horizon Therapeutics plc (Nasdaq: HZNP) today announced it ranked No. 1 on the Fortune Best Workplaces in Biopharma 2021 list. This is the fifth consecutive year Horizon has been named to the list and... 
From Business Wire News Releases
Screen Of The Day: These Growth Stocks Make Bullish Moves Amid Soaring Profits
Those looking for growth stocks to watch are always trying to discover top stocks making bullish moves amid rising profit estimates. Here are some ideas. 
From Investor's Business Daily
Horizon Therapeutics plc Named as One of the Best Workplaces in Ireland
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been recognized as one of the Best Workplaces in Ireland 2021 by Great Place to Work Ireland, ranking No. 12 in the small company... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.